Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
relugolix + docetaxel + prednisone
- Development stage
- Unknown
- Lead developer
- Myovant Sciences
- Modality
- Small Molecules
- Administration
- Oral (relugolix), Intravenous (docetaxel), Oral (prednisone)
01
Overview
Relugolix + docetaxel + prednisone is a combination regimen used in the treatment of advanced prostate cancer. **Relugolix** is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that rapidly suppresses testosterone production, minimizing tumor flare compared to GnRH agonists[1][2]. **Docetaxel** is a cytotoxic chemotherapeutic agent from the taxane class, inhibiting microtubule depolymerization, thereby blocking mitosis and promoting cell death. **Prednisone** is a synthetic glucocorticoid used as anti-inflammatory and immunosuppressive support, also helping to mitigate docetaxel-induced side effects. This three-drug combination is employed as part of androgen deprivation therapy (ADT) alongside cytotoxic therapy and steroid support for metastatic hormone-sensitive and castration-resistant prostate cancer, with substantial clinical and real-world data supporting safety and maintenance of testosterone suppression. Relugolix, especially, offers oral administration and a favorable cardiovascular profile compared to injectable GnRH agonists[1][2][3].
- Other names
- relugolix + docetaxel + prednisone
02
Targets
GR (Glucocorticoid receptor)GnRHR (Gonadotropin-releasing hormone receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on relugolix + docetaxel + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on relugolix + docetaxel + prednisone.